Investigative Ophthalmology & Visual Science,
Год журнала:
2024,
Номер
65(14), С. 41 - 41
Опубликована: Дек. 27, 2024
Purpose:
This
review
explores
the
role
of
pigment
epithelium-derived
factor
(PEDF)
in
retinal
degenerative
and
vascular
disorders
assesses
its
potential
both
as
an
adjunct
to
established
endothelial
growth
inhibiting
treatments
for
diseases
a
neuroprotective
therapeutic
agent.
Methods:
A
comprehensive
literature
was
conducted,
focusing
on
anti-angiogenic
properties
PEDF.
The
evaluated
effects
health,
dysregulation
ocular
disorders,
application
preclinical
models.
Advances
drug
delivery,
including
gene
therapy,
were
also
examined.
Results:
PEDF,
initially
identified
promoting
neuronal
differentiation,
is
potent
endogenous
angiogenesis
inhibitor.
Strong
are
observed
studies.
It
has
pro-apoptotic
antiproliferative
cells
thereby
reducing
neovascularization.
Although
promising,
clinical
development
limited
with
only
single
conducted
phase
I
trial
macular
Development
PEDF-derived
peptides
enhances
potency
specificity,
emerging
therapy
approaches
offer
sustained
PEDF
expression
long-term
treatment.
However,
questions
regarding
dosage,
durability,
efficacy
remain,
particularly
large
animal
Conclusions:
shows
significant
models
degeneration
disorders.
Despite
inconclusive
evidence
downregulation
primary
disease
driver,
many
studies
highlight
benefits
favorable
safety
profile.
could
enable
long-acting
PEDF-based
treatments,
but
further
research
needed
optimize
dosage
potentially
leading
trials
expanding
treatment
options
Experimental Gerontology,
Год журнала:
2024,
Номер
196, С. 112556 - 112556
Опубликована: Авг. 27, 2024
The
aim
of
this
study
was
to
evaluate
the
potential
protective
effect
Qiju
Granule
in
a
rat
model
age-related
macular
degeneration
(AMD)
and
investigate
underlying
mechanisms
involved.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 17, 2024
Abstract
Although
age-related
macular
degeneration
(AMD)
is
the
most
common
blinding
disease
in
elderly
population,
there
are
still
many
unknowns
pathophysiology
of
this
disease.
This
also
reflected
by
a
lack
convincing
treatment
options
against
subtype,
dry
AMD.
Oxidative
stress
and
hypoxia
retinal
pigment
epithelium
(RPE)
hallmarks
Previously,
we
have
shown
that
combination
these
two
risk
factors,
i.e.
hypoxidative
stress,
exacerbates
RPE
cell
death
ferroptosis.
Hypoxia
leads
to
stabilization
hypoxia-inducible
factors
(HIFs),
key
regulators
cellular
adaptation
hypoxic
conditions.
In
present
study,
therefore
investigated
roles
HIF-1
HIF-2
on
human
line
under
stress.
For
purpose,
conducted
siRNA-mediated
knockdowns
α-subunits
HIF-2.
We
found
especially
iron
metabolism
was
affected
HIF-1α
silencing,
resulting
decreased
levels
ferroptosis
susceptibility.
Surprisingly,
heme
oxygenase
1
(HO-1)
superoxide
dismutase
2
(SOD2)
contributed
death.
observed
metabolism,
which
usually
impaired
AMD
cells,
improved
silencing.
Furthermore,
identified
an
FDA-approved
small
molecule
inhibitor,
Vorinostat,
fully
rescue
cells
from
stress-induced
conclusion,
study
highlights
importance
considering
targeted
HIF
inhibition
as
promising
approach
for
treating
degeneration.
Nutrients,
Год журнала:
2024,
Номер
16(21), С. 3747 - 3747
Опубликована: Окт. 31, 2024
:
Observational
studies
have
noted
that
patients
with
certain
retinal
degenerative
diseases
exhibit
iron
disturbances
in
the
retina
or
vitreous
compared
to
healthy
controls.
However,
connection
between
serum
status
and
these
remains
unclear.
This
study
aims
explore
potential
causal
relationship
biomarkers
development
of
age-related
macular
degeneration
(AMD),
retinitis
pigmentosa
(RP),
diabetic
retinopathy
(DR).
Investigative Ophthalmology & Visual Science,
Год журнала:
2024,
Номер
65(14), С. 41 - 41
Опубликована: Дек. 27, 2024
Purpose:
This
review
explores
the
role
of
pigment
epithelium-derived
factor
(PEDF)
in
retinal
degenerative
and
vascular
disorders
assesses
its
potential
both
as
an
adjunct
to
established
endothelial
growth
inhibiting
treatments
for
diseases
a
neuroprotective
therapeutic
agent.
Methods:
A
comprehensive
literature
was
conducted,
focusing
on
anti-angiogenic
properties
PEDF.
The
evaluated
effects
health,
dysregulation
ocular
disorders,
application
preclinical
models.
Advances
drug
delivery,
including
gene
therapy,
were
also
examined.
Results:
PEDF,
initially
identified
promoting
neuronal
differentiation,
is
potent
endogenous
angiogenesis
inhibitor.
Strong
are
observed
studies.
It
has
pro-apoptotic
antiproliferative
cells
thereby
reducing
neovascularization.
Although
promising,
clinical
development
limited
with
only
single
conducted
phase
I
trial
macular
Development
PEDF-derived
peptides
enhances
potency
specificity,
emerging
therapy
approaches
offer
sustained
PEDF
expression
long-term
treatment.
However,
questions
regarding
dosage,
durability,
efficacy
remain,
particularly
large
animal
Conclusions:
shows
significant
models
degeneration
disorders.
Despite
inconclusive
evidence
downregulation
primary
disease
driver,
many
studies
highlight
benefits
favorable
safety
profile.
could
enable
long-acting
PEDF-based
treatments,
but
further
research
needed
optimize
dosage
potentially
leading
trials
expanding
treatment
options
